Patent Grant
8460255
The disclosure relates in general to a device and method for wound therapy that is capable of treating a variety of chronic and acute wound types, including, but not limited to, infection wounds, venous ulcers, arterial ulcers, diabetic ulcers, burn wounds, post amputation wounds, surgical wounds, and the like. Specifically, the present disclosure is related to wound treatment devices and methods that utilize negative pressure therapy.
Negative pressure therapy has been one tool used for the treatment of a variety of wounds by practitioners in the art. Conventional devices are generally large in size and often require the use of complicated equipment such as suction pumps, vacuum pumps and complex electronic controllers. Other associated equipment may include wound liquid/exudate collection canisters, liquid transporting conduits, and pressure regulators/transducers/sensors. As a result, such devices may be bulky, power intensive, relatively costly and substantially non-disposable. Furthermore, the complexity of conventional devices requires steady patient supervision and that initial placement and any changing of the devices be conducted by a physician or nurse. At present, a typical cost for the use of these devices is on the order of about $100 per day per patient.
The rising costs of healthcare and of medical devices place pressure on patients and care providers alike to seek out solutions that allow use by a patient in-home, with less supervision. Furthermore, patients continue to demand devices that are more easily portable to allow travel and mobility.
The present disclosure provides a self-integrated wound therapy device for providing negative pressure therapy to a wound. In one embodiment, the device may include a housing to cover at least a portion of a wound. The device may also include a liquid collector within a liquid retention chamber and an adaptor or coupling for coupling to a vacuum source. The vacuum connection may be in gaseous communication with the liquid-retention chamber. The vacuum connection may be separated from the liquid collector by a liquid barrier. The wound therapy device may also include a seal to seal the housing to a body surface of a patient.
The vacuum connection in some embodiments may be coupled to a vacuum source that may be optionally located within or adjacent to the housing. In other embodiments, the vacuum connection may comprise an adapter that may be coupled to a vacuum source located external to the housing. As used throughout this specification, adapter and coupler or coupling may be used interchangeably.
In other embodiments, the wound therapy device may be modular in nature, optionally including a wound interface module, a retention module and a vacuum source module. Each module of the wound therapy device may be optionally replaceable individually or in combination.
The present embodiments will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that the accompanying drawings depict only typical embodiments, and are, therefore, not to be considered to be limiting of the scope of the present disclosure, the embodiments will be described and explained with specificity and detail in reference to the accompanying drawings as provided below.
It will be readily understood that the components of the embodiments as generally described and illustrated in the Figures herein could be arranged and designed in a wide variety of different configurations. Thus, the following more detailed description of various embodiments, as represented in the Figures, is not intended to limit the scope of the present disclosure, but is merely representative of various embodiments. While the various aspects of the embodiments are presented in drawings, the drawings are not necessarily drawn to scale unless specifically indicated.
The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.
Reference throughout this specification to features, advantages, or similar language does not imply that all of the features and advantages that may be realized with the present invention should be or are in any single embodiment of the invention. Rather, language referring to the features and advantages is understood to mean that a specific feature, advantage, or characteristic described in connection with an embodiment is included in at least one embodiment of the present invention. Thus, discussion of the features and advantages, and similar language, throughout this specification may, but do not necessarily, refer to the same embodiment.
Furthermore, the described features, advantages, and characteristics of the invention may be combined in any suitable manner in one or more embodiments. One skilled in the relevant art will recognize that the invention can be practiced without one or more of the specific features or advantages of a particular embodiment. In other instances, additional features and advantages may be recognized in certain embodiments that may not be present in all embodiments of the invention.
Reference throughout this specification to “one embodiment,” “an embodiment,” or similar language means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases “in one embodiment,” “in an embodiment,” and similar language throughout this specification may, but do not necessarily, all refer to the same embodiment.
In the following description, numerous specific details are provided, such as examples of housings, barriers, chambers etc., to provide a thorough understanding of embodiments of the invention. One skilled in the relevant art will recognize, however, that the invention can be practiced without one or more of the specific details, or with other methods, components, materials, and so forth. In other instances, well-known structures, materials, or operations such as vacuum sources are not shown or described in detail to avoid obscuring aspects of the invention.
Referring now to
In one embodiment the housing 20 is rigid or semi-rigid. The housing 20 of the device 10 substantially retains its size and structure during the application of negative pressure, thus allowing a vacuum to be held within the housing 20. The housing 20 may be produced out of any suitable material known to one of ordinary skill in the art, including, without limitation, rubbers, including polyurethane, and dense plastics such as, but not limited to, polypropylene, polyvinyl chlorides, polyethylene, acrylonitrile-based copolymer, such as those sold under the Barex® brand, polyester, polystyrene, polyether, nylon, polychlorotrifluoroethylene, fluoropolymer, polytetrafluoroethylene, such as those sold under the Teflon® brand, silicone, neoprene or combinations thereof and similar materials.
In another embodiment, the housing 20 is made of a flexible barrier or a surface wrap supported by at least one customizable rigid or semi-rigid structural support (not shown) present within the internal space 22 of the housing to maintain the shape of the device when the device is subjected to pressure lower than atmospheric pressure. In some embodiments, the structural supports may be external to the housing or integral with the housing 20. The flexible barrier or surface wrap may be a thin polyurethane film with a dermal compatible adhesive supported by structural foam present within the internal space 22 of the housing 20. The structural supports or structural foam can be made from rigid or semi-rigid plastics and foams, e.g., polystyrene, polyester, polyether, polyethylene, silicone, neoprene, combinations thereof, and the like. Alternatively, the liquid-retention chamber 40 or a liquid collector positioned therein may by itself provide the needed structural support to maintain vacuum passages within the housing 20 open upon application of vacuum.
In one embodiment, the housing 20 is semi-permeable. An exemplary semi-permeable housing 20 may be substantially impermeable to liquids but somewhat permeable to water vapor and other gases while capable of maintaining a negative pressure underneath the housing 20 upon application of a vacuum. By way of example, the housing 20 material may be constructed of polyurethane or other semi-permeable material such as those sold under the Tegaderm® brand. In one embodiment the housing 20 may have a water vapor transmission rate (“WVTR”) of about 836 grams/m2/day or more. However, in other embodiments the WVTR may be less than about 836 grams/m2/day. In yet other embodiments, the housing 20 material may be substantially impermeable to both liquids and gases (including water vapor). Other exemplary housing materials may include materials sold under the Opsite®, Suresite®, Medfix®, and Mefilm® brand names.
The device may be made of material to make it conformable for use with wounds in various locations. For example, the wound may be on an elbow or other joint such the device may need to be conformed to make a good seal around the wound site.
The vacuum source (not shown) is in fluid communication with the housing 20. A vacuum connection 30 may connect the housing 20 and the vacuum source. The vacuum connection may include without limitation, flexible or semi-rigid medical tubing known in the art, a plenum, a conduit, or other passage capable of transmitting the vacuum from the vacuum source to the housing 20. In one embodiment, the housing is fitted with an adaptor 32 or coupling 32 that allows the housing 20 to be attached to the vacuum connection 30 or to an external vacuum source. The vacuum source may be located internal to or external to the housing 20 and may be remote or adjacent to the housing. Where the vacuum source is external to the housing 20 and adjacent the housing 20, the vacuum connection 30 may not be necessary and the vacuum may be communicated to the housing 20 directly from the vacuum source through the adapter 32 or coupling 32. In embodiments, wherein the vacuum source is within the housing 20, the adapter 32 or coupling 32 may not be needed. The vacuum source may be a micro-vacuum pump or a regular vacuum pump. The pumps may be of any kind known to those skilled in the art. The vacuum source may also be an osmotic or electroosmotic pump.
The vacuum source may include and operably be coupled to a power source or supply, such as a battery. Power sources referred to herein may be, for example, electrical outlets, batteries, and/or rechargeable batteries and the like. The batteries may be integral (non-replaceable), replaceable and/or rechargeable. The power source may be located adjacent to the vacuum source or may be positioned remotely so that a larger capacity power source that could last for the duration of the treatment can be used.
The adapter 32 or coupling 32 can simply be a vacuum port for connecting an outlet of the vacuum source. The adapter 32 or coupling 32 can also be configured to provide more complex communication between the housing 20 and the vacuum source. The adapter 32 or coupling 32 may be fitted to carry communication channels and/or lines between a control module in the vacuum source or vacuum source module and sensors positioned within the interior of the housing 20.
In one embodiment, the adapter 32 or coupling 30 is in gaseous communication with the vacuum chamber 24, which in turn is in communication with the liquid-retention chamber 40 via the liquid barrier 36. In an alternative embodiment, the vacuum connection 30 is directly in communication with the liquid-retention chamber 40 via the liquid barrier 36. In another alternative embodiment, the outlet of the vacuum source is directly connected to the liquid barrier. The vacuum source, the vacuum 30 connection and the vacuum chamber 24 and the liquid barrier 36 may all be external or internal to the housing.
The adapter 32 or coupling 32 may be a design feature associated with the housing 20 or vacuum source to allow the housing 20 and vacuum source to be coupled together. This coupling may be accomplished by interference fit, snap fit, compression fit, and the like. The adapter 32 or coupling 32 may also be accomplished by adhesion or a by mechanical device as is known in the art to provide a coupling for maintaining the vacuum source in communication with the housing. The adapter 32 or coupling 32 is configured to transfer negative pressure generated by the vacuum source to the housing 20.
The vacuum chamber 24 of the embodiment of device 10 illustrated in
The liquid collector includes at least one porous material that includes a plurality of passages to allow fluid communication between the vacuum source and the wound through the liquid collector. The liquid collector may include structures and/or substances to assist in retaining the liquids drawn from the wound. Such structures and/or substances may include sponges, foams, fibers, wicking fibers, hollow fibers, beads, fabrics, or gauzes, super-absorbent materials including super-absorbent polymers in various forms, absorbent foams, gelling agents such as sodium carboxy methyl cellulose, packing materials, and combinations thereof. Such structures or substances have passages that permit the flow of gas and allow the vacuum or negative pressure to be applied to the wound. These structures or substances also absorb and retain liquid drawn out of the wound. It will be appreciated by those of skill in the art that liquid in the form of wound exudate may include solid components such as cellular debris and other solids that are typically found in wound exudates.
The materials or structures that make up the liquid collector form or contain interstitial spaces that serve as negative pressure passageways. These allow the vacuum source to be in fluid communication with the wound through the liquid collector. In one embodiment, the liquid collector may be a composite structure of fibers made of polyester or rayon with superabsorber fibers made of sodium polyacrylate among others dispersed throughout the structure to form a fiber matrix. The superabsorber fibers or particles are distributed discretely within the fiber matrix such that the gas (vacuum) passage ways are open even after substantial liquid uptake by the superabsorber fibers or particles. The superabsorber fibers may act as, or contain, nodes within the liquid collector. As liquid is absorbed by the liquid collector, the liquid collects at the super absorber nodes without blocking the gas (vacuum) passageways within the liquid collector. In another embodiment, the wound exudates that enter the liquid collector are absorbed by the superabsorber material and are immobilized at discrete locations within the fiber matrix or other liquid collector material. Thus, the liquid collector retains the liquid during the application of vacuum as well as when the vacuum is off.
In another embodiment, the liquid collector has areas or zones that are prevented from becoming saturated or super saturated. In these embodiments, the non saturated zones or areas make up the passages for communication vacuum or negative pressure from the vacuum source through the liquid collector to the wound. Accordingly, the device 10 includes means for maintaining a therapeutic pressure at the wound while the liquid collector is absorbing liquid.
In one embodiment, the liquid collector, housing 30, and/or liquid retention chamber 40 is sufficiently rigid to allow fluid communication between the vacuum source and the wound through the liquid collector when the device is subject to a pressure lower than atmospheric pressure. The device 10 has sufficient rigidity or structure so that the passages through the liquid collector will remain open under vacuum pressure, thus allowing vacuum or negative pressure to be transmitted to the wound.
The liquid collector is configured to retain liquid under a predetermined amount of mechanical force applied to the liquid collector. For example, the liquid collector may retain liquid even when the device 10 is squeezed by a user. This feature prevents oozing of free liquid from the liquid collector when the vacuum source is off or when the retention chamber or liquid collector needs to be replaced.
In one embodiment, the liquid collector is a composite structure made of a structural fiber matrix with superabsorber fibers dispersed within. Such a structure maintains sufficient structural integrity under the application of vacuum to keep vacuum passages open. Hence no additional structural supports are needed.
Other means for collecting and retaining liquid having similar features that are known to one of ordinary skill in the art may also be used. In some embodiments, the liquid collector or the liquid-retention chamber 40 may be antimicrobial in nature or may include antimicrobial agents.
The liquid collector may be within the liquid-retention chamber 40, or may be part of the structure that defines the liquid-retention chamber 40. As used herein, “retaining liquid” or “the retention of liquid” means substantially retaining the liquid. In some embodiments, the liquid-retention chamber itself can provide the needed structural support to maintain vacuum passages within or through the housing open upon application of vacuum. Thus, the device has sufficient structure to maintain the functionality of the device under application of a vacuum. As will be discussed in greater detail below, a fill indicator may alert the user at a predetermined liquid collector saturation point.
The liquid barrier 36, in one embodiment, is positioned between the vacuum source and the liquid collector (not shown). The liquid barrier 36 serves to prevent travel of liquid from the liquid-retention chamber 40 to the vacuum chamber 24. The liquid barrier 36 may also be a gas permeable membrane. As such, it may comprise any of a large family of suitable technologies that prevent travel of liquid from the liquid-retention chamber 40 into the vacuum chamber 24 while allowing gas flow, and thus transmission of negative pressure provided through the vacuum connection 30. It will be appreciated by those of skill in the art that the liquid barrier 36 may be in the form of a film, a mat, a membrane or other structure that is liquid impermeable. For example, the liquid barrier 36 may include a poroys hydrophobic film, a porous hydrophobic membrane, or other hydrophobic structure, or other ways to preclude moisture travel.
Examples of porous hydrophobic films include, but are not limited to, porous and microporous polytetrafluoroethylene, polypropylene, polyvinylidene difluoride, acrylic polymers, polyethylene, or fibrous layers of each and combinations thereof. For example, porous hydrophobic films sold under the Gore-Tex® or Millipore® brands may be suitable. These hydrophobic films may also act as anti-microbial filters and prevent passage of bacteria from the liquid-retention chamber to the vacuum source and vice versa. Other technologies that allow gas flow but prevent liquid flow may also be used as suitable liquid barriers 36 as would be apparent to those having skill in the art with the aid of the present disclosure.
In the device 10 of
In one embodiment, the wound therapy device 10 includes means for maintaining operation of the device independent of device orientation. For example the device may need to be located at various locations on the patient's body and must function at different angles including when the device is completely inverted. In one embodiment, the means for maintaining the functionality of the device independent of device orientation includes the liquid barrier 36 which keeps moisture out of the vacuum source regardless of device orientation. The means also includes the individual components of the device which are designed to be orientation independent. The means for maintaining the device operation independent of the device orientation may include the liquid collector being fabricated from a material which gels and immobilizes the wound exudates thereby preventing clogging of vacuum passageways by the free liquid. For example, where the liquid collector includes a fibrous matrix with supper absorber nodes dispersed throughout the matrix, the exudate may gel at the nodes removing the liquid while continually providing vacuum passageways.
The device 10 may additionally contain a wound interface 41 in direct contact with the wound and may comprise single or multiple layers of varying thicknesses to accommodate the depth of the wound. The wound interface 41 may be either placed directly inside the wound or over the wound. The wound interface 41 is in fluid communication with the liquid-retention chamber and is configured to transfer wound fluid from a wound bed to the liquid-retention chamber 40. In one embodiment, the wound interface 41 transfers fluid by wicking action. In another embodiment, the wound interface 41 transfers fluid by capillary action. The wound interface 41 may be porous to allow wound fluid to pass through for absorption by the overlying liquid collector. Alternatively, the wound interface 41 may partially or fully absorb wound fluids. The wound interface 41 may be a sheet, a foam, a gel, a gauze, a porous matrix, a honeycomb, a mop, confetti, and combinations thereof.
The wound interface 41 may be either placed directly inside the wound or over the wound. The wound interface 41 may serve many functions such as being a layer that allows supply of vacuum to the wound while allowing easy and painless removal from the wound site of the liquid-retention chamber 40 after it reaches a predetermined absorption level. The wound interface 41 may be degradable copolymer foil, such as those sold under the Topkin® brand, or a layer that provides beneficial bioagents in the form of specialized dressings such as dermal regeneration templates (e.g., those sold under the Integra® brand), bioabsorbable gels, foams and barriers that prevent tissue adhesion (e.g., those sold under the Incert® brand), a skin substitute (e.g., those sold under the BioFill® brand), a layer for selectively maintaining moisture at the wound site (e.g., alginates or dressings such as those sold under the Alevyn® brand), a layer that is angiogenic (e.g., those sold under the Theramers® brand), and/or a layer that is antimicrobial or includes an antimicrobial agent.
The wound interface 41 may take a variety of forms including but not limited to a sheet, foam, gel, gauze or other space filling porous structures such as a pouch of beads, a shaggy mop, loose confetti or a honey comb. Alternatively, the wound interface 41 can be a gel that fills the wound cavity, which turns into a porous structure on application of the vacuum. In one embodiment, the wound therapy device includes a surface in contact with the wound having at least one pore larger than about 100 microns in diameter.
It will be appreciated by those of skill in the art that the wound interface 41 and liquid collector may be combined in a variety of ways to accomplish the teachings of the invention. For example, the wound interface 41 and liquid collector may be separate layers of an integral body. In one embodiment, a plurality of the liquid collectors may each be enclosed within a pouch that acts as the wound interface. The cover of the pouch is fabricated from the wound interface formed from a porous material that is permeable to vacuum and body fluids. Liquid collector material is enclosed within this porous pouch. In one embodiment the wound interface prevents direct contact between the liquid collector material and the wound. However, it is contemplated that in some embodiments there may be some contact. This wound interface/liquid retention combination can take many forms including pillows, tubes, self-contained tubular structures and similar structures where the liquid collector can be enveloped in the wound interface. These structures are flexible and can be formed into a suitable shape to fit any kind of wound cavity. Alternatively, several of these pouches can be linked together or otherwise combined to form structures that can be inserted into a deep wound tunnel or deep wound cavity. For example, a linked tubular chain can be formed that can be inserted within a wound tunnel such that the entire wound cavity is filled with this chained structure. A flexible barrier housing material such as Tegaderm can then be used to cover the wound site and seal on the skin around the wound site. The module containing the vacuum source is attached to the flexible barrier housing to create vacuum within the wound cavity. Wound exudate enters the inside of the pouch through the permeable outer wound interface cover and gets absorbed within the liquid collector. As before, the liquid collector will permit application of vacuum to the wound while absorbing and retaining liquid drawn out of the wound.
As will be discussed in greater detail below, the device 10 may include a skin protection layer. The skin protection layer may protect the healthy skin around the wound from bruising or maceration due to undesirable exposure of the healthy skin to vacuum and moisture during wound therapy. Such a skin protection layer will allow the healthy skin to “breathe” and also allows easy and painless removal of the device from the wound site. The skin protection layer may be sealed separately to the skin first and the housing may be then sealed to the skin protection layer. Alternatively, the skin protection layer may be integral to the housing or the wound interface. The skin protection layer may be the same as the housing material or may be a gel.
When the device 10 is placed on a patient and activated, or attached to an external vacuum source via a vacuum connection 30 or simply through an adapter 32, the device 10 delivers negative pressure to the wound. The device 10 is generally attached to the body surface of a patient using one of a variety of seals known in the art, such as, in one embodiment, a housing seal 28. The housing 20 of the device 10 may be adapted to be sealed to a body surface of a patient. In some embodiments, this sealing may occur simply as a result of placing the housing 20 against the body surface and drawing a vacuum within the device 10. The device 10 may include a seal 28 for attaching the device to a surface. Adhesives, gaskets, and other seals or sealing technologies known to one of ordinary skill in the art may also be used as a seal 28 including the use of adhesive backed thin polyurethane films. Other suitable seals are known to those of ordinary skill in the art and may be used with the embodiments disclosed. In one embodiment, the device includes a leak detector in operable communication with the seal to determine whether vacuum or negative pressure is escaping from the device 10 out the seal 28.
In one embodiment, the seal 28 may be part of housing 20 or may be integral with the skin protection layer. It will be appreciated by those of skill in the art that the seal 28, housing 20 and skin protection layer may be combined in a variety of different ways to accomplish the teachings of this invention.
Thus, in operation, the device 10 may be applied to a wound site of a patient like a patch, wherein a vacuum source coupled to the vacuum connection 30, provides negative pressure to the wound. Prior to use, the device 10 may be packaged to prevent contamination. Such packaging could be a bag or envelope, or could include the use of an optional protective cover 16, with an optional pull tab 18 that is removed from the device prior to placement on the patient. During application of negative pressure to the wound site, liquid is drawn into the liquid-retention chamber 40 and held within the liquid-retention chamber 40, being prevented from further travel by the liquid barrier 36.
Referring now to
More specifically, the vacuum chamber 124 may be a cylindrically-shaped void within the internal space 122 of the housing 120, which, due to its size, prevents liquid from traveling from the liquid-retention chamber 140 into the vacuum passage 130. The vacuum passage 130 may extend into the vacuum chamber 124, and may include at least one orifice 138. The housing 120 may also include internal supports 126 that extend between the vacuum passage 130 and the perimeter 142 of the liquid-retention chamber 140 to maintain proper distance between the vacuum passage 130 and the liquid-retention chamber 140.
A labyrinth may also be used as a liquid barrier to prevent liquid from leaving the liquid retention chamber 140. The labyrinth approach utilizes the principle of coalescence and employs structures used in commercially available mist eliminators as are well understood by chemical engineers. Liquid or mist that enters the labyrinth will coalesce and will be redirected back to the liquid retention chamber without entering the vacuum passage 130.
The wound therapy device of
Referring again to
The exemplary structure, shape, and construction of the vacuum chamber 124 of the device 110 is further illustrated in
The liquid barriers and/or vacuum chamber configurations described above include passages that form part of the passage between the vacuum source and the wound that carries the negative pressure to the wound. Accordingly, these configurations form part of the means for communicating a vacuum between the vacuum source and the wound.
Referring next to
In some embodiments, negative pressure may be applied to the liquid-retention chamber 240 and/or liquid collector via a tube or other coupling 232 or adapter 232 attached to the vacuum pump 234. When the vacuum source 230 is an internally-placed vacuum pump 234, the coupling 232 may travel from the pump 234 to the vacuum chamber 224 in gaseous communication with the liquid-retention chamber 240. When the vacuum source 230 is an internally-placed vacuum pump 234, an outlet 235 is provided for the vacuum pump or other vacuum source to vent. The outlet may include a filter 237 to prevent germs from outside from entering inside or vice-versa. The opening of the coupling 232 in the vacuum chamber 224 may include a filter 261 or can have similar properties to the liquid barrier 236 (such as, in some embodiments, as an antimicrobial filter) to prevent wound liquids from reaching the vacuum source 230 and to prevent any outside germs from entering the wound site. Moreover, in some embodiments the device 210 may include both inlet and outlet filters to prevent venting of microorganisms outside the housing 220.
In operation, the wound therapy device 210 may first be placed on a body surface of a patient so as to at least partially enclose a wound area. As discussed above, the device 210 may be sealed to the body surface using either just the suction generated by the device 210 alone, or using a seal 228 chosen from those known to those skilled in the art. The seal 228 illustrated in
Following attachment of the device 210 to a patient, the vacuum source 234 is activated, reducing the internal pressure of the device 210. As negative pressure is generated, liquids are drawn from the wound into the liquid-retention chamber 240 of the device 210, and are blocked from further progress into the vacuum chamber 224 or the negative pressure source 230 by the liquid barrier 236. As in the previous embodiments, the liquid barrier 236 may be any of those known to those of ordinary skill in the art, including, without limitation, porous hydrophobic films, membranes, and porous hydrophobic structures such as sponges and/or foams.
The exemplary device 210 of
The wound healing device 210 may alternatively include a pressure controller for controlling the vacuum or pressure with in the housing 220. The pressure controller may work in cooperation with a vacuum (pressure) sensor to detect the pressure within the wound cavity and/or over the wound within the liquid-retention chamber 240. The vacuum sensor is connected to the vacuum source 234 via a circuit board/relay combination and controls the vacuum source. The vacuum sensor may alternatively be coupled to the pressure relief (control) valve 260 to maintain therapeutic vacuum at the wound site. Vacuum (pressure) sensors or differential pressure sensors may provide a voltage output or a current output which signal can be used by a circuit board/relay combination to turn on or turn off the vacuum source. Examples of such electronic vacuum sensors are those commercially available from Honeywell under the trade name Sensotec sensors.
Alternatively, a vacuum switch or a differential pressure switch may be placed that shuts off the vacuum source 30 when the desired pressure is reached without any pressure relief valve. Such mechanical vacuum (pressure) switches are well known for practitioners of the art and can be purchased from MPL (Micro Pneumatic Logic), Air Troll, Air Logic among others.
In still other embodiments, the device 210 may include a fill indicator that indicates when the liquid-retention chamber 240 has a predetermined absorption level. The fill indicator 270 may operate in a variety of ways known to one of ordinary skill in the art. Such indicators include those that are visible (e.g., color change or LED) or audible. The fill indicator 270 may be advantageously placed on the external wall of the housing 220 or near the vacuum source 234. The fill indicator 270 may include a sensor component positioned inside the housing that communicates electronically or mechanically with the fill indicator. Such a sensor may be placed either between the liquid-retention chamber 240 and the liquid barrier 236 or on the wall of the liquid-retention chamber opposite to the wound interface 241. Some sensors operate by detecting presence of free moisture in the liquid-retention chamber 240, which denotes that the liquid-retention chamber has reached a predetermined absorption level. Alternatively, the fill indicator sensor may use electrical conductivity through a path in a portion of the liquid-retention chamber 240 to sense when moisture has reached the zone and provide a signal to shut off the vacuum source 230. Other sensors are known in the art and are suitable for use with the devices disclosed, including color-change technology based upon moisture content of the material or a change in a physical feature or characteristic, vacuum sensors based on detection of vacuum changes, galvanic, potentiometric, and capacitive types. The device 210 may additionally include an overflow valve such as a float valve for the vacuum connection to prevent transmission of liquid into the vacuum source.
The wound healing device 210 may also alternatively include a lack of vacuum or housing non-seal indicator or leak indicator (not shown). Such an indicator may be based on pump run-time, low vacuum signal from the vacuum sensor, visible indicators on the housing (e.g., a dimple on the housing that flattens or an embossed pattern on the housing that appears when the vacuum inside is at the appropriate level), low flow rate sensors, pressure sensitive color change, etc. The leak indicator may be in operable communication with the seal. The wound healing device 210 may also optionally include a sensor to detect oxygen levels or other gasses and a sensor to measure temperature at the wound site. The device 210 may also include a blood detector. In one embodiment, the blood detector may use optical technologies known in the art to detect the presence of blood within the housing 220.
In embodiments with sensors, other indicators, valves, switches, and the like, the adapter may be configured with channels, ports, inlets or outlets. For example, the adapter 232 may include communication leads from a vacuum sensor, fill indicator sensor, seal sensor or other sensors or indicators present in the interior of the housing 220. Further, any communications between a pressure relief valve or over-flow valve present on the housing 20 and the vacuum source can be channeled through such an adapter. In some embodiments, the adapter can also function as an on-off switch where the vacuum source as well as all the other components in the device will start functioning when the vacuum source is coupled to the housing 20 through the adapter.
In this embodiment, the negative pressure source 430 extends through the housing 420 into the vacuum chamber 424 at an outlet 432. The outlet 432 may include a filter 461 (such as, in some embodiments, an antimicrobial filter) to prevent entry of wound exudate into the vacuum source 434. As with the other embodiments, this device 410 may include a liquid barrier 436, such as a hydrophobic membrane, that prevents flow of liquid into the vacuum chamber 424, but allows the negative pressure to extend into the liquid-retention chamber 440, causing liquid to be drawn into the liquid-retention chamber 440 from the wound. In some embodiments, the vacuum chamber 424 may include a porous hydrophobic foam. In other embodiments, the vacuum chamber 424 may be empty.
As described herein, the device 410 may be sealed to the body surface of a patient using either just the suction generated by the device 410 alone, or using a seal 428 chosen from those known to individuals skilled in the art. The seal 428 illustrated in
To accomplish this, the device 510 shown in
The wound interface 541 located at the wound site seals the wound and allows application of negative pressure to the wound site. The wound interface 541 may be in contact with the liquid-retention chamber 540 which extends to the location of the vacuum supply chamber 524. This extended liquid-retention chamber 540 allows the placement of the negative pressure source at a different location compared to a wound site.
Alternatively, the device 510 may have two separate housings: one housing 520a having a sealing surface 512 around the wound site and the other housing 520b being located at some distance away from the wound site. The latter housing 520b may or may not seal to the skin. Both housings 520a, 520b shown in
The negative pressure source 530 may include a micro-vacuum pump 534 operably coupled to a power source 538, such as a battery. The negative pressure source 530 may be external to the housing 520, as illustrated. However, it should be understood that alternative embodiments of the wound therapy device 510 may include the pump 534 which maybe a micro-vacuum pump and/or power source 538 internal to the housing 520. The negative pressure source 530 may be an osmotic or electroosmotic pump adjacent or internal to or adjacent the housing as discussed above.
For example, if the liquid-retention module 640, 640′ is filled to a predetermined level with exudate, it may be replaced with a new liquid-retention module 640, 640′, while keeping the functional vacuum pump module 630, 630′. Alternatively, the liquid-retention module 640, 640′ may be replaced at regular intervals to prevent overflow and assure appropriate capacity. Likewise, the wound interface module 641, 641′ may be replaced independent of the other modules.
In the embodiment of
The wound interface module 641, 641′ of both embodiments may serve many functions as described above, such as being a layer or other structure that allows supply of vacuum to the wound while allowing easy and painless removal from the wound site during dressing changes. Alternatively, the wound interface may be a layer or other structure that provides beneficial bioagents in the form of specialized dressings such as dermal regeneration templates, bioabsorbable gels, foams and barriers that prevent tissue adhesion. The wound interface may also be a skin substitute, a layer for selectively maintaining moisture at the wound site, a layer that is angiogenic, and a layer that is antimicrobial. The wound interface may take a variety of forms, including, but not limited to a sheet, foam, gel, gauze or a porous matrix.
The vacuum source module 911 includes a housing 933 containing a vacuum source 934, a vacuum switch 944 and a power supply 938. A vacuum source outlet 930 and a vacuum supply inlet 952 for the vacuum switch 944 are connected to the vacuum chamber 924 through the apertures 925 provided in the flexible barrier housing 920. The vacuum switch 944 can be replaced by a vacuum sensor/circuit board/relay combination. It is contemplated that the tubes can be releasably attached to the vacuum chamber to allow the modules 911 and 913 to be detached from one another.
The coupling 1048 is configured to transfer negative pressure generated by the vacuum source module 1011 to the dressing module 1013. The coupling 1048 may include a lip or other structural element of either the vacuum source module 1011 or the dressing module 1013. The coupling 1048 may also be a separate member. The coupling allows the vacuum source module 1011 to be attached to and maintain communication with the dressing module 1013. In one embodiment, the vacuum source module 1011 is press fit into the dressing module 1013. In another embodiment, the dressing module 1013 is press fit into the vacuum source module 1011. The modules 1011 and 1013 may cooperate in threaded engagement with each other. The modules 1011 and 1013 may also be snap fit together or be bonded to one another in addition to other types of engagements. It will be appreciated by those of skill in the art that the modules 1011 and 1013 may be attached to each other in a variety of ways in order to practice the teachings of this invention.
The vacuum source module 1011 includes a housing 1033 containing a vacuum source 1034, a vacuum switch 1044 and a power supply 1038. The housing 1033 is provided with two apertures 1025—one for the vacuum outlet 1030 of the vacuum source 1034 and the other for the vacuum supply inlet 1052 for the vacuum switch 1044. Two liquid barrier films 1036 are positioned at apertures 1025. In one embodiment, the vacuum source module housing 1033 is attached to the dressing module housing 1020 using water-barrier adhesive 1048 such that the apertures in the first housing and the second housing lineup with the liquid barrier film in-between. This embodiment is different from earlier embodiments due to the absence of a vacuum chamber within the first housing, i.e. the vacuum connection 1030 is directly in communication with the liquid-retention chamber 1040 via the liquid barrier 1036. The vacuum switch can be replaced by a vacuum sensor/circuit board/relay combination. A fill indicator 1070 along with a sensor 1066 is also shown.
The device 1210 may include a moisture disperser 1280 and a vacuum disperser 1282. The moisture disperser 1280 may facilitate even absorption of wound fluids by the liquid-retention chamber 1240 and/or liquid collector. The vacuum disperser 1282 may facilitate even distribution of vacuum within the liquid-retention chamber 1240 and/or liquid collector. Examples of such vacuum dispersion and moisture dispersers 1282, 1280 include the three-dimensional Knit Spacer Fabrics manufactured by Gehring Textiles. These spacer fabrics may include two separate face fibers that are combined, in a single knitting sequence, with an inner spacer yarn that has a relative perpendicular orientation to the face fibers. Face fibers can be made of, but are not limited to: cotton, nylon, polyester, neoprene, monofilament spandex, PBI, Nomex, Kevlar and fiberglass.
In one embodiment, the vacuum disperser is a surfactant applied to the liquid collector. The vacuum disperser may also be a hydrophobic structure positioned at the inlet of negative pressure into the housing 1220. It will be appreciated by those of skill in the art that the vacuum disperser may preclude the occlusion of the inlet by liquid collector material.
The retention chamber 1240 and/or the liquid collector 1242 may be single or multi layered. For example, it may be composed of the liquid collector 1242, the vacuum disperser 1282 and the moisture disperser 1280. These layers may be present between the liquid collector 1242 and the liquid barrier 1236 (or vacuum chamber 1224) or between the absorption layer 1242 and the wound bed.
Without limitation, it is believed that the disclosed devices and their methods of use may be useful for the therapy of surface wounds on a patient. These wounds may include, but are not limited to, infectious wounds, burn wounds, venous and arterial ulcers, diabetic ulcers and wounds, post-surgical wounds, bed sore wounds, and the like. Additionally, such devices are contemplated for use in a variety of fields, as would be contemplated by one of ordinary skill in the art.
According to one method of wound treatment or therapy utilizing the devices described herein, a device having a housing with a liquid-retention chamber is positioned above at least a portion of the wound. Negative pressure may be applied to the wound using the vacuum source. Wound liquids or exudate may be collected in the liquid-retention chamber. Additionally, the device may be replaced when it is filled with liquid. In modular embodiments, the liquid-retention chamber module, wound interface module, or the vacuum source may be replaced separately or in combination as needed.
A method of assembling a wound therapy device includes the steps of providing a vacuum source module comprising a vacuum source capable of generating negative pressure and a pressure controller for controlling the amount of negative pressure. The method also includes providing a dressing module having a housing to cover at least a portion of a wound site. The dressing module also includes a porous liquid collector positioned within the housing and in communication with the wound site. The liquid collector is configured to retain wound exudate while simultaneously communicating negative pressure generated by the vacuum source module to the wound site. The dressing module may also include a liquid barrier positioned between the liquid collector and the vacuum source module. The dressing module may further include a seal for sealing the dressing module to a surface around the wound site. The method includes securing the vacuum source module to the dressing module, such that the vacuum source module transfers negative pressure to the dressing module and attaching the device adjacent a wound site. It will be appreciated by those of skill in the art that the method steps may be practiced in a number of different orders to practice the teachings of the invention.
In some of the embodiments disclosed, the devices may be adapted to be inexpensive, light-weight, and either partially or entirely disposable. Further, the devices may be adapted to be simple to operate, such that in some instances, a patient could place the device with some reduced degree of medical supervision. In addition to the above, the devices may be constructed so as to be used without attention to their orientation.
It is contemplated that the devices may take a variety of forms, including those that are completely disposable when full, or partially disposable such as, for example, either the vacuum source or the liquid-retention chamber. In embodiments such as device 10 of
It should be noted that although the housings disclosed have been illustrated in particular shapes, such as being generally rounded, the housings are not necessarily limited to particular shape, and may be constructed in any advantageous shape. In some embodiments, the devices may be sized and shaped such that the vacuum chamber or liquid-retention chamber is capable of sealing over the patient's wound, at least in part. The housings and the seals disclosed may be configured to hold a vacuum when the device is placed and sealed over at least a portion of a wound on a patient's body surface. Such seals may be substantially air-tight to prevent the entry of microbes but do not need to be absolutely impermeable. It is contemplated that vacuum pressure will either be continuously or periodically applied to maintain a therapeutic negative pressure therapy range.
When the vacuum is switched on after placing the device on a patient's wound, air is removed around the wound, generating a vacuum within the housing cavity. At the same time, wound-liquid absorbing material may begin absorbing the exudate/liquids in the wound. Sustained negative pressure over a wound region may promote tissue migration and wound closure. In some embodiments, the devices may be shaped like a patch or bandage that may be changed more than once a day. It will be appreciated by those of skill in the art that the device may continue to absorb and trap fluid when the device or vacuum is switched off.
Additionally, the device may contain a fill indicator that senses the presence of free moisture in the liquid-retention chamber that signals that the optional porous pad has reached a predetermined absorptive level. The fill indicator may in turn be coupled to an over-flow valve to prevent wound liquids from reaching the vacuum pump or it may provide a signal used to prompt disabling the pump.
In all of the above embodiments, when the devices are adapted to be disposable, they may be discarded after use in part or in whole. Indeed multiple disposable devices can be provided to a patient for a treatment plan, which may consist of a plurality of individual treatments with disposable devices over a predetermined period.
Without further elaboration, it is believed that one skilled in the art can use the preceding description to utilize the present disclosure to its fullest extent. The examples and embodiments disclosed herein are to be construed as merely illustrative and not a limitation of the scope of the present disclosure in any way. It will be apparent to those having skill in the art that changes may be made to the details of the above-described embodiments without departing from the underlying principles of the disclosure provided herein. In other words, various modifications and improvements of the embodiments specifically disclosed in the description above are within the scope of the appended claims. Note that elements recited in means-plus-function format are intended to be construed in accordance with 35 U.S.C. §112 ¶6. The scope of the invention is therefore defined by the following claims.
This application is a divisional application of U.S. patent application Ser. No. 11/610,458 filed Dec. 13, 2006 now U.S. Pat. No. 7,779,625 which is a continuation-in-part of, and claims priority to, U.S. patent application Ser. No. 11/432,855 filed on May 11, 2006, and now U.S. Pat. No. 7,615,036, both of which are incorporated herein by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 695270 | Beringer | Mar 1902 | A |
| 1480562 | Mock | Jan 1924 | A |
| 2280915 | Johnson | Apr 1942 | A |
| 2367690 | Purdy | Jan 1945 | A |
| 2568933 | Robbins | Sep 1951 | A |
| 2632443 | Lesher | Mar 1953 | A |
| 2682873 | Evans et al. | Jul 1954 | A |
| 3367332 | Groves | Feb 1968 | A |
| 3486504 | Austin et al. | Dec 1969 | A |
| 3572340 | Lloyd et al. | Mar 1971 | A |
| 3610238 | Rich et al. | Oct 1971 | A |
| 3874387 | Barbieri | Apr 1975 | A |
| 3993080 | Loseff | Nov 1976 | A |
| 4102342 | Akiyama et al. | Jul 1978 | A |
| 4112947 | Nehring | Sep 1978 | A |
| 4136696 | Nehring | Jan 1979 | A |
| 4184510 | Murry et al. | Jan 1980 | A |
| 4217894 | Franetzki | Aug 1980 | A |
| 4219019 | Coates | Aug 1980 | A |
| 4224945 | Cohen | Sep 1980 | A |
| 4250882 | Adair | Feb 1981 | A |
| 4316466 | Babb | Feb 1982 | A |
| 4382441 | Svedman | May 1983 | A |
| 4465485 | Kashmer et al. | Aug 1984 | A |
| 4468227 | Jensen | Aug 1984 | A |
| 4525166 | Leclerc | Jun 1985 | A |
| 4534356 | Papadakis | Aug 1985 | A |
| 4551141 | McNeil | Nov 1985 | A |
| 4573965 | Russo | Mar 1986 | A |
| 4608041 | Nielsen | Aug 1986 | A |
| 4655766 | Theeuwes et al. | Apr 1987 | A |
| 4681562 | Beck et al. | Jul 1987 | A |
| 4710165 | McNeil et al. | Dec 1987 | A |
| 4778446 | Jensen | Oct 1988 | A |
| 4778456 | Lokken | Oct 1988 | A |
| 4792328 | Beck et al. | Dec 1988 | A |
| 4795435 | Steer | Jan 1989 | A |
| 4820284 | Hauri | Apr 1989 | A |
| 4921488 | Maitz et al. | May 1990 | A |
| 4936834 | Beck et al. | Jun 1990 | A |
| 4950483 | Ksander et al. | Aug 1990 | A |
| 4969880 | Zamierowski | Nov 1990 | A |
| 4972829 | Knerr | Nov 1990 | A |
| 4979944 | Luzsicza | Dec 1990 | A |
| 4994022 | Steffler et al. | Feb 1991 | A |
| 5055198 | Shettigar | Oct 1991 | A |
| 5056510 | Gilman | Oct 1991 | A |
| 5073172 | Fell | Dec 1991 | A |
| 5100396 | Zamierowski | Mar 1992 | A |
| 5149331 | Ferdman et al. | Sep 1992 | A |
| 5152757 | Eriksson | Oct 1992 | A |
| 5167613 | Karami et al. | Dec 1992 | A |
| 5176663 | Svedman et al. | Jan 1993 | A |
| 5215519 | Shettigar | Jun 1993 | A |
| 5261893 | Zamierowski | Nov 1993 | A |
| 5266928 | Johnson | Nov 1993 | A |
| 5279608 | Cherif Cheikh | Jan 1994 | A |
| 5328614 | Matsumura | Jul 1994 | A |
| 5358494 | Svedman | Oct 1994 | A |
| 5380280 | Peterson | Jan 1995 | A |
| 5437651 | Todd et al. | Aug 1995 | A |
| 5445604 | Lang | Aug 1995 | A |
| 5489280 | Russell | Feb 1996 | A |
| 5498338 | Kruger et al. | Mar 1996 | A |
| 5527293 | Zamierowski | Jun 1996 | A |
| 5549584 | Gross | Aug 1996 | A |
| 5562107 | Lavender et al. | Oct 1996 | A |
| 5636643 | Argenta et al. | Jun 1997 | A |
| 5643189 | Masini | Jul 1997 | A |
| 5645081 | Argenta et al. | Jul 1997 | A |
| 5678564 | Lawrence et al. | Oct 1997 | A |
| 5733337 | Carr et al. | Mar 1998 | A |
| 5759570 | Arnold | Jun 1998 | A |
| 5785688 | Joshi et al. | Jul 1998 | A |
| 5830496 | Freeman | Nov 1998 | A |
| 5833646 | Masini | Nov 1998 | A |
| 5843011 | Lucas | Dec 1998 | A |
| 5857502 | Buchalter | Jan 1999 | A |
| 5868933 | Patrick et al. | Feb 1999 | A |
| 5876611 | Shettigar | Mar 1999 | A |
| 5964723 | Augustine | Oct 1999 | A |
| 6071267 | Zamierowski | Jun 2000 | A |
| 6103951 | Freeman | Aug 2000 | A |
| 6110197 | Augustine et al. | Aug 2000 | A |
| 6135116 | Vogel et al. | Oct 2000 | A |
| D434150 | Turney et al. | Nov 2000 | S |
| 6142982 | Hunt et al. | Nov 2000 | A |
| 6168800 | Dobos et al. | Jan 2001 | B1 |
| 6176307 | Danos et al. | Jan 2001 | B1 |
| 6225523 | Masini | May 2001 | B1 |
| 6254567 | Treu et al. | Jul 2001 | B1 |
| 6255552 | Cummings et al. | Jul 2001 | B1 |
| 6261283 | Morgan et al. | Jul 2001 | B1 |
| 6287521 | Quay et al. | Sep 2001 | B1 |
| 6345623 | Heaton et al. | Feb 2002 | B1 |
| 6398767 | Fleischmann | Jun 2002 | B1 |
| 6402724 | Smith et al. | Jun 2002 | B1 |
| 6450773 | Upton | Sep 2002 | B1 |
| 6458109 | Henley et al. | Oct 2002 | B1 |
| 6465708 | Augustine | Oct 2002 | B1 |
| 6471685 | Johnson | Oct 2002 | B1 |
| 6471982 | Lydon et al. | Oct 2002 | B1 |
| 6482491 | Samuelsen et al. | Nov 2002 | B1 |
| 6491684 | Joshi et al. | Dec 2002 | B1 |
| 6553998 | Heaton et al. | Apr 2003 | B2 |
| 6599262 | Masini | Jul 2003 | B1 |
| 6648862 | Watson | Nov 2003 | B2 |
| 6673028 | Argenta et al. | Jan 2004 | B1 |
| 6676610 | Morton et al. | Jan 2004 | B2 |
| 6685681 | Lockwood et al. | Feb 2004 | B2 |
| 6695823 | Lina et al. | Feb 2004 | B1 |
| 6695824 | Howard et al. | Feb 2004 | B2 |
| 6752794 | Lockwood et al. | Jun 2004 | B2 |
| 6755807 | Risk, Jr. et al. | Jun 2004 | B2 |
| 6764462 | Risk, Jr. et al. | Jul 2004 | B2 |
| 6767334 | Randolph | Jul 2004 | B1 |
| 6814079 | Heaton et al. | Nov 2004 | B2 |
| 6824533 | Risk, Jr. et al. | Nov 2004 | B2 |
| 6855135 | Lockwood et al. | Feb 2005 | B2 |
| 6856821 | Johnson | Feb 2005 | B2 |
| 6936037 | Bubb | Aug 2005 | B2 |
| 6951553 | Bubb et al. | Oct 2005 | B2 |
| 6977323 | Swenson | Dec 2005 | B1 |
| 6979324 | Bybordi et al. | Dec 2005 | B2 |
| 6994702 | Johnson | Feb 2006 | B1 |
| 7004915 | Boynton et al. | Feb 2006 | B2 |
| 7022113 | Lockwood et al. | Apr 2006 | B2 |
| 7067709 | Murata et al. | Jun 2006 | B2 |
| 7070584 | Johnson et al. | Jul 2006 | B2 |
| 7077832 | Fleischmann | Jul 2006 | B2 |
| 7087806 | Scheinberg et al. | Aug 2006 | B2 |
| 7108683 | Zamierowski | Sep 2006 | B2 |
| 7118545 | Boyde | Oct 2006 | B2 |
| 7128735 | Weston | Oct 2006 | B2 |
| 7195624 | Lockwood | Mar 2007 | B2 |
| 7214202 | Vogel et al. | May 2007 | B1 |
| 7216651 | Argenta et al. | May 2007 | B2 |
| 7361184 | Joshi | Apr 2008 | B2 |
| 7381859 | Hunt et al. | Jun 2008 | B2 |
| 7438705 | Karpowicz et al. | Oct 2008 | B2 |
| 7494482 | Orgill et al. | Feb 2009 | B2 |
| 7524315 | Blott et al. | Apr 2009 | B2 |
| 7534240 | Johnson | May 2009 | B1 |
| 7534927 | Lockwood | May 2009 | B2 |
| 7569742 | Haggstrom et al. | Aug 2009 | B2 |
| 7611500 | Lina et al. | Nov 2009 | B1 |
| 7615036 | Joshi et al. | Nov 2009 | B2 |
| 7645253 | Gura et al. | Jan 2010 | B2 |
| 7645269 | Zamierowski | Jan 2010 | B2 |
| 7699823 | Haggstrom et al. | Apr 2010 | B2 |
| 7699830 | Martin | Apr 2010 | B2 |
| 7708724 | Weston | May 2010 | B2 |
| 7717313 | Criscuolo et al. | May 2010 | B2 |
| 7753894 | Blott et al. | Jul 2010 | B2 |
| 7759537 | Bishop et al. | Jul 2010 | B2 |
| 7759538 | Fleischmann | Jul 2010 | B2 |
| 7759539 | Shaw et al. | Jul 2010 | B2 |
| 7775998 | Riesinger | Aug 2010 | B2 |
| 7776028 | Miller et al. | Aug 2010 | B2 |
| 7779625 | Joshi et al. | Aug 2010 | B2 |
| 7790945 | Watson, Jr. | Sep 2010 | B1 |
| 7790946 | Mulligan | Sep 2010 | B2 |
| 7794438 | Henley et al. | Sep 2010 | B2 |
| 7794450 | Blott et al. | Sep 2010 | B2 |
| 7815616 | Boehringer et al. | Oct 2010 | B2 |
| 7825289 | Vess | Nov 2010 | B2 |
| 7828782 | Suzuki | Nov 2010 | B2 |
| 7838717 | Haggstrom et al. | Nov 2010 | B2 |
| 7846141 | Weston | Dec 2010 | B2 |
| 7862339 | Mulligan | Jan 2011 | B2 |
| 7883494 | Martin | Feb 2011 | B2 |
| 7909805 | Weston | Mar 2011 | B2 |
| 7959624 | Riesinger | Jun 2011 | B2 |
| 7964766 | Blott et al. | Jun 2011 | B2 |
| 7976519 | Bubb et al. | Jul 2011 | B2 |
| 7998125 | Weston | Aug 2011 | B2 |
| 8062272 | Weston | Nov 2011 | B2 |
| 8062273 | Weston | Nov 2011 | B2 |
| 8080702 | Blott et al. | Dec 2011 | B2 |
| 8100887 | Weston | Jan 2012 | B2 |
| 8105295 | Blott et al. | Jan 2012 | B2 |
| 8118794 | Weston | Feb 2012 | B2 |
| 8128615 | Blott | Mar 2012 | B2 |
| 8152785 | Vitaris | Apr 2012 | B2 |
| 8162907 | Heagle | Apr 2012 | B2 |
| 8162909 | Blott et al. | Apr 2012 | B2 |
| 8235955 | Blott et al. | Aug 2012 | B2 |
| 20010016205 | Shimizu | Aug 2001 | A1 |
| 20010029956 | Argenta | Oct 2001 | A1 |
| 20010034499 | Sessions et al. | Oct 2001 | A1 |
| 20020065494 | Lockwood et al. | May 2002 | A1 |
| 20020068913 | Fleischmann | Jun 2002 | A1 |
| 20020115952 | Tumey et al. | Aug 2002 | A1 |
| 20020120185 | Johnson | Aug 2002 | A1 |
| 20020143286 | Tumey | Oct 2002 | A1 |
| 20020150720 | Howard et al. | Oct 2002 | A1 |
| 20020161346 | Lockwood et al. | Oct 2002 | A1 |
| 20020183702 | Henley et al. | Dec 2002 | A1 |
| 20020198503 | Risk et al. | Dec 2002 | A1 |
| 20020198504 | Risk et al. | Dec 2002 | A1 |
| 20030014022 | Lockwood et al. | Jan 2003 | A1 |
| 20030014025 | Allen et al. | Jan 2003 | A1 |
| 20030021775 | Freeman | Jan 2003 | A1 |
| 20030040687 | Boynton et al. | Feb 2003 | A1 |
| 20030050594 | Zamierowski | Mar 2003 | A1 |
| 20030088202 | Gilman | May 2003 | A1 |
| 20030097086 | Gura | May 2003 | A1 |
| 20030108587 | Orgill et al. | Jun 2003 | A1 |
| 20030125649 | McIntosh et al. | Jul 2003 | A1 |
| 20030144619 | Augustine | Jul 2003 | A1 |
| 20030171675 | Rosenberg | Sep 2003 | A1 |
| 20030175798 | Raees et al. | Sep 2003 | A1 |
| 20030208149 | Coffey | Nov 2003 | A1 |
| 20030212357 | Pace | Nov 2003 | A1 |
| 20030212431 | Brady et al. | Nov 2003 | A1 |
| 20030225347 | Argenta et al. | Dec 2003 | A1 |
| 20040019342 | Nagasuna et al. | Jan 2004 | A1 |
| 20040030304 | Hunt et al. | Feb 2004 | A1 |
| 20040039391 | Argenta et al. | Feb 2004 | A1 |
| 20040039415 | Zamierowski | Feb 2004 | A1 |
| 20040054338 | Bybordi et al. | Mar 2004 | A1 |
| 20040064132 | Boehringer et al. | Apr 2004 | A1 |
| 20040122434 | Argenta et al. | Jun 2004 | A1 |
| 20040127834 | Sigurjonsson et al. | Jul 2004 | A1 |
| 20040127862 | Bubb et al. | Jul 2004 | A1 |
| 20040127863 | Bubb et al. | Jul 2004 | A1 |
| 20040167482 | Watson | Aug 2004 | A1 |
| 20040225208 | Johnson | Nov 2004 | A1 |
| 20040241214 | Kirkwood et al. | Dec 2004 | A1 |
| 20040249353 | Risks, Jr. et al. | Dec 2004 | A1 |
| 20050004534 | Lockwood et al. | Jan 2005 | A1 |
| 20050010153 | Lockwood et al. | Jan 2005 | A1 |
| 20050020955 | Sanders et al. | Jan 2005 | A1 |
| 20050028828 | Heaton et al. | Feb 2005 | A1 |
| 20050058694 | Nielsen | Mar 2005 | A1 |
| 20050070835 | Joshi | Mar 2005 | A1 |
| 20050080372 | Nielsen et al. | Apr 2005 | A1 |
| 20050090787 | Risk, Jr. et al. | Apr 2005 | A1 |
| 20050148913 | Weston | Jul 2005 | A1 |
| 20050222527 | Miller et al. | Oct 2005 | A1 |
| 20050261643 | Bybordi et al. | Nov 2005 | A1 |
| 20060015087 | Risk, Jr. et al. | Jan 2006 | A1 |
| 20060025727 | Boehringer et al. | Feb 2006 | A1 |
| 20060029650 | Coffey | Feb 2006 | A1 |
| 20060041247 | Petrosenko et al. | Feb 2006 | A1 |
| 20060069365 | Sperl et al. | Mar 2006 | A1 |
| 20060079852 | Bubb et al. | Apr 2006 | A1 |
| 20060100586 | Karpowicz et al. | May 2006 | A1 |
| 20060100594 | Adams et al. | May 2006 | A1 |
| 20060116620 | Oyaski | Jun 2006 | A1 |
| 20060149170 | Boynton et al. | Jul 2006 | A1 |
| 20070010797 | Nishtala et al. | Jan 2007 | A1 |
| 20070038172 | Zamierowski | Feb 2007 | A1 |
| 20070055209 | Patel et al. | Mar 2007 | A1 |
| 20070141128 | Blott et al. | Jun 2007 | A1 |
| 20070167884 | Mangrum et al. | Jul 2007 | A1 |
| 20070179460 | Adahan | Aug 2007 | A1 |
| 20070185426 | Ambrosio et al. | Aug 2007 | A1 |
| 20070185463 | Mulligan | Aug 2007 | A1 |
| 20070219532 | Karpowicz et al. | Sep 2007 | A1 |
| 20070265585 | Joshi et al. | Nov 2007 | A1 |
| 20070265586 | Joshi et al. | Nov 2007 | A1 |
| 20080004549 | Anderson et al. | Jan 2008 | A1 |
| 20080004559 | Riesinger | Jan 2008 | A1 |
| 20080039759 | Holm et al. | Feb 2008 | A1 |
| 20080077091 | Mulligan | Mar 2008 | A1 |
| 20080082059 | Fink et al. | Apr 2008 | A1 |
| 20080108977 | Heaton et al. | May 2008 | A1 |
| 20080119802 | Riesinger | May 2008 | A1 |
| 20080167593 | Fleischmann | Jul 2008 | A1 |
| 20080183119 | Joshi | Jul 2008 | A1 |
| 20080188820 | Joshi | Aug 2008 | A1 |
| 20080208147 | Argenta et al. | Aug 2008 | A1 |
| 20080223378 | Henderson et al. | Sep 2008 | A1 |
| 20080306407 | Taylor | Dec 2008 | A1 |
| 20080306456 | Riesinger | Dec 2008 | A1 |
| 20090005746 | Nielsen et al. | Jan 2009 | A1 |
| 20090036873 | Nielsen et al. | Feb 2009 | A1 |
| 20090054855 | Blott et al. | Feb 2009 | A1 |
| 20090054856 | Mormino et al. | Feb 2009 | A1 |
| 20090069759 | Blott et al. | Mar 2009 | A1 |
| 20090125004 | Shen et al. | May 2009 | A1 |
| 20090131888 | Joshi | May 2009 | A1 |
| 20090177135 | Rogers et al. | Jul 2009 | A1 |
| 20090192499 | Weston et al. | Jul 2009 | A1 |
| 20090198201 | Adahan | Aug 2009 | A1 |
| 20090216170 | Robinson et al. | Aug 2009 | A1 |
| 20090221977 | Blott et al. | Sep 2009 | A1 |
| 20090227968 | Vess | Sep 2009 | A1 |
| 20090227969 | Jaeb et al. | Sep 2009 | A1 |
| 20090234306 | Vitaris | Sep 2009 | A1 |
| 20090234307 | Vitaris | Sep 2009 | A1 |
| 20090234309 | Vitaris et al. | Sep 2009 | A1 |
| 20090240185 | Jaeb et al. | Sep 2009 | A1 |
| 20090240218 | Braga et al. | Sep 2009 | A1 |
| 20090254053 | Svensby et al. | Oct 2009 | A1 |
| 20090254054 | Blott et al. | Oct 2009 | A1 |
| 20090264837 | Adahan | Oct 2009 | A1 |
| 20090270820 | Johnson et al. | Oct 2009 | A1 |
| 20090299251 | Buan | Dec 2009 | A1 |
| 20090299255 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20090299256 | Barta et al. | Dec 2009 | A1 |
| 20090299257 | Long et al. | Dec 2009 | A1 |
| 20090299306 | Buan | Dec 2009 | A1 |
| 20090299307 | Barta et al. | Dec 2009 | A1 |
| 20090299341 | Kazala, Jr. et al. | Dec 2009 | A1 |
| 20090299342 | Cavanaugh, II et al. | Dec 2009 | A1 |
| 20090306580 | Blott et al. | Dec 2009 | A1 |
| 20090312723 | Blott et al. | Dec 2009 | A1 |
| 20090312728 | Randolph et al. | Dec 2009 | A1 |
| 20090326487 | Vitaris | Dec 2009 | A1 |
| 20100010477 | Augustine et al. | Jan 2010 | A1 |
| 20100036334 | Heagle et al. | Feb 2010 | A1 |
| 20100036367 | Krohn | Feb 2010 | A1 |
| 20100042074 | Weston et al. | Feb 2010 | A1 |
| 20100063483 | Adahan | Mar 2010 | A1 |
| 20100063484 | Heagle | Mar 2010 | A1 |
| 20100069858 | Olson | Mar 2010 | A1 |
| 20100069863 | Olson | Mar 2010 | A1 |
| 20100087767 | McNeil | Apr 2010 | A1 |
| 20100100063 | Joshi et al. | Apr 2010 | A1 |
| 20100100075 | Weston et al. | Apr 2010 | A1 |
| 20100106114 | Weston et al. | Apr 2010 | A1 |
| 20100121286 | Locke et al. | May 2010 | A1 |
| 20100122417 | Vrzalik et al. | May 2010 | A1 |
| 20100125258 | Coulthard et al. | May 2010 | A1 |
| 20100150991 | Bernstein | Jun 2010 | A1 |
| 20100160879 | Weston | Jun 2010 | A1 |
| 20100185163 | Heagle | Jul 2010 | A1 |
| 20100207768 | Pidgeon et al. | Aug 2010 | A1 |
| 20100249733 | Blott et al. | Sep 2010 | A9 |
| 20100268198 | Buan et al. | Oct 2010 | A1 |
| 20100274207 | Weston | Oct 2010 | A1 |
| 20100278518 | Gordon | Nov 2010 | A1 |
| 20100280468 | Haggstrom et al. | Nov 2010 | A1 |
| 20100286635 | Watson, Jr. | Nov 2010 | A1 |
| 20100286638 | Malhi | Nov 2010 | A1 |
| 20100298866 | Fischvogt | Nov 2010 | A1 |
| 20100305490 | Coulthard et al. | Dec 2010 | A1 |
| 20100305524 | Vess et al. | Dec 2010 | A1 |
| 20100318043 | Malhi et al. | Dec 2010 | A1 |
| 20100324510 | Andresen et al. | Dec 2010 | A1 |
| 20100324516 | Braga et al. | Dec 2010 | A1 |
| 20100331797 | Patet et al. | Dec 2010 | A1 |
| 20110004172 | Eckstein et al. | Jan 2011 | A1 |
| 20110009835 | Blott | Jan 2011 | A1 |
| 20110015593 | Svedman et al. | Jan 2011 | A1 |
| 20110028918 | Hartwell | Feb 2011 | A1 |
| 20110028921 | Hartwell et al. | Feb 2011 | A1 |
| 20110034892 | Buan | Feb 2011 | A1 |
| 20110046584 | Haggstrom et al. | Feb 2011 | A1 |
| 20110054421 | Hartwell | Mar 2011 | A1 |
| 20110054422 | Locke et al. | Mar 2011 | A1 |
| 20110054423 | Blott et al. | Mar 2011 | A1 |
| 20110087176 | Blott | Apr 2011 | A2 |
| 20110087178 | Weston | Apr 2011 | A2 |
| 20110087180 | Weston | Apr 2011 | A2 |
| 20110092927 | Wilkes et al. | Apr 2011 | A1 |
| 20110092958 | Jacobs | Apr 2011 | A1 |
| 20110105963 | Hu et al. | May 2011 | A1 |
| 20110106030 | Scholz | May 2011 | A1 |
| 20110112492 | Bharti et al. | May 2011 | A1 |
| 20110118683 | Weston | May 2011 | A1 |
| 20110130712 | Topaz | Jun 2011 | A1 |
| 20110172615 | Greener et al. | Jul 2011 | A2 |
| 20110230849 | Coulthard et al. | Sep 2011 | A1 |
| 20110251567 | Blott et al. | Oct 2011 | A1 |
| 20110282309 | Adie et al. | Nov 2011 | A1 |
| 20120053538 | Blott et al. | Mar 2012 | A1 |
| 20120109084 | Blott et al. | May 2012 | A1 |
| 20120157942 | Weston | Jun 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 2198243 | Feb 1996 | CA |
| 2367460 | Oct 2000 | CA |
| 2390513 | May 2001 | CA |
| 2121688 | Jul 2001 | CA |
| 2408305 | Nov 2001 | CA |
| 2458285 | Mar 2003 | CA |
| 2157772 | Sep 2003 | CA |
| 2809828 | Sep 1978 | DE |
| 3 935 818 | May 1991 | DE |
| 4 012 232 | Oct 1991 | DE |
| 198 44 355 | Apr 2000 | DE |
| 0 020 662 | Jul 1984 | EP |
| 0 355 186 | Feb 1990 | EP |
| 0 777 504 | Oct 1998 | EP |
| 0 782 421 | Jul 1999 | EP |
| 1 897 569 | Aug 2002 | EP |
| 0 708 620 | May 2003 | EP |
| 1 088 569 | Aug 2003 | EP |
| 1 440 667 | Mar 2006 | EP |
| 1 284 777 | Apr 2006 | EP |
| 1 171 065 | Mar 2007 | EP |
| 1 476 217 | Mar 2008 | EP |
| 1 121 163 | Nov 2008 | EP |
| 2098257 | Sep 2009 | EP |
| 1163907 | Oct 1958 | FR |
| 114754 | Apr 1918 | GB |
| 641061 | Aug 1950 | GB |
| 1224009 | Mar 1971 | GB |
| 1549756 | Aug 1979 | GB |
| 2195255 | Apr 1988 | GB |
| 2378392 | Feb 2003 | GB |
| 2415908 | Jan 2006 | GB |
| 2003-165843 | Jun 2003 | JP |
| 1251912 | Apr 1983 | SU |
| WO 8401904 | May 1984 | WO |
| WO 9011795 | Oct 1990 | WO |
| WO 9100718 | Jan 1991 | WO |
| WO 9220299 | Nov 1992 | WO |
| WO 9605873 | Feb 1996 | WO |
| WO 9901173 | Jan 1999 | WO |
| WO 0007653 | Feb 2000 | WO |
| WO 0050143 | Aug 2000 | WO |
| WO 0059424 | Oct 2000 | WO |
| WO 0119430 | Mar 2001 | WO |
| WO 0134223 | May 2001 | WO |
| WO 01037922 | May 2001 | WO |
| WO 0185248 | Nov 2001 | WO |
| WO 0193793 | Dec 2001 | WO |
| WO 02083046 | Oct 2002 | WO |
| WO 02092783 | Nov 2002 | WO |
| WO 03045492 | Jun 2003 | WO |
| WO 03057307 | Jul 2003 | WO |
| WO 03092620 | Nov 2003 | WO |
| WO 2004024300 | Mar 2004 | WO |
| WO 2004037334 | May 2004 | WO |
| WO 2005025666 | Mar 2005 | WO |
| WO 2005051461 | Jun 2005 | WO |
| WO 2005070480 | Aug 2005 | WO |
| WO 2005082435 | Sep 2005 | WO |
| WO 2007024230 | Mar 2007 | WO |
| WO 2007030601 | Mar 2007 | WO |
| WO 2009066105 | May 2009 | WO |
| WO 2009066106 | May 2009 | WO |
| WO 2012022484 | Feb 2012 | WO |
| Entry |
|---|
| US 6,306,115, 10/2001, Kelly et al. (withdrawn) |
| U.S. Appl. No. 60/559,727, filed Apr. 5, 2004, Publication Date Apr. 5, 2004, Richard Scott Weston. |
| U.S. Appl. No. 60/573,655, filed May 21, 2004, Publication Date May 21, 2004, Richard Scot Weston. |
| U.S. Appl. No. 10/599,720, Publication Date Oct. 6, 2006, Blott et al. |
| U.S. Appl. No. 12/192,000, Publication Date Aug. 14, 2008, Hartwell et al. |
| U.S. Appl. No. 13/287,897, Publication Date Nov. 2, 2011, Adie et al. |
| U.S. Appl. No. 13/287,959, Publication Date Nov. 2, 2011, Allen et al. |
| Achterberg, V., Ph.D., Hydroactive dressings and serum proteins: an in vitro study, Journal of Wound Care, February, vol. 5, No. 2, 1996 (pp. 79-82). |
| Argenta, Louis C., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment; Clinical Experience”, Ann Plas Surg 1997;38:563-577 (Dec. 10, 1996). |
| Aubrey, D.A., et al., Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation, Arch. Surg., Oct. 1984, 119, 1141-1144. |
| Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvashia State University, Cheboksary, USSR 1986) pp. 94-96 (with English translation). |
| Biblehimer, Helen L., “Dealing With a Wound that Drains 1.5 Liters a Day,” RN, Aug. 1986, pp. 21-23, USA. |
| Bier, A., Hyperemia as a Therapeutic Agent, Ed. Dr. Gustavus M. Blech, A. Robertson & Co., Chicago 1905, pp. 74-85. |
| Brubacher, “To Heal a Draining Wound”, RN Mar. 1982, 7 pages. |
| Bucalo et al. “Inhibition of Cell Proliferation by Chronic Wound Fluid.” Wound Repair and Regeneration, Miami, 1993, pp. 181-186. |
| Canadian Office Action for Canadian Application No. 2739605 dated Aug. 22, 2011 in 2 pages. |
| Chariker, M.E., et al, “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery. Jun. 1989, pp. 59-63, vol. 34 USA. |
| Chinese Office Action dated Aug. 29, 2008 for Patent Application No. 200480032101.1. |
| Chintamani, et al., “Half versus full vacuum suction drainage after modified radical mastectomy for breast cancer- a prospective randomized clinical trial”, Research Article (Jan. 27, 2005), 1-5. |
| Costunchenok, BM, Effect of Vacuum on Surgical Purulent Wounds, Vestnik Chirurgia, 1986, 6 pages. |
| Davydov et al. “Pathogenic Mechanisms of the Effect of Vacuum Therapy on the Course of the Wound Process” pp. 43-46 (Dec. 1990). |
| Davydov, Yu A., et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 15-17. |
| Davydov, Yu A., et al., “The Bacteriological and Cytological Assessment of Vacuum Therapy of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 11-14. |
| Davydov, Yu A., et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 5-7. |
| De Lange, M.Y., et al., “Vacuum-Assisted Closure: Indications and Clinical Experience”, Eur J Plast Surg (2000) 2;178-182 (Feb. 9, 2000). |
| Dilmaghani et al., “A Method for Closed Irrigation and Suction Therapy in Deep Wound Infections,” Journal of Bone and Joint Surgery, 1969, vol. 51-A, No. 2, pp. 323-342. |
| EPO, Office Action for EP App. No. 04 791 592.1 dated Jun. 12, 2008. |
| EPO, Second European Office Action for EP App. No. 04 791 592.1 dated Feb. 10, 2011. |
| Fleischmann, Vacuum sealing: indication, technique, and results, European Journal of Orthopaedic Surgery & Traumatology (1995), pp. 37-40. |
| Fleischmann, W. Wund Forum Spezial. IHW '94. “Vakuumversiegelung zur Behandlung von Problemwuden” (with English translation: Vacuum Sealing for Treatment of Problematical Wounds). |
| Garcia-Rinaldi, R., et al., Improving the Efficiency of Wound Drainage Catheters, Amer. Journ. of Surg., Sep. 1975, pp. 130, 372-373. |
| Hartz, R.S., et al., Healing of the Perineal Wound, Arch. Surg., Apr. 1980, 115, 471-474. |
| Health Technology, Literature R., “Vacuum Assisted Closure Therapy for Wound Care”, Health Technology Literature Review (Dec. 2004), 3-59. |
| International Preliminary Report for International Application No. PCT/GB/2004/004549, dated Dec. 20, 2005. |
| International Search Report for International Application No. PCT/GB/2004/004549, dated Feb. 21, 2005. |
| Japanese Office Action dated Aug. 25, 2009 for Patent Application No. 2006-537411. |
| Japanese Office Action dated Dec. 15, 2009 for Patent Application No. 2006-537411. |
| Japanese Office Action dated Jun. 22, 2010 for Patent Application No. 2006-537411. |
| Japanese Office Action dated Jan. 17, 2012 for Patent Application No. 2010-59188. |
| Jeter, K.F., et al, “Managing Draining Wounds and Fistulae: New and Established Methods”, Chronic Wound Care, pp. 240-246. |
| Johnson, F.E., An Improved Technique for Skin Graft Placement using a Suction Drain, Surgery, Gynecology and Obstetrics, Dec. 1984, 3 pages. |
| KCI Inc., If It's Not VAC Therapy, It's Not Negative Pressure Wound Therapy, Jan. 2005. |
| Khirugii, Vestnik, “A Collection of Published Studies Complementing the Research and Innovation of Wound Care”, The Kremlin Papers, Perspectives in Wound Care, Russian Medical Journal, Vestnik Khirugii, Blue Sky Publishing (2004), 2-17. |
| Kostiuchenok, B. M., et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 3-4. |
| Landes, R.R. and I. Melnick, An Improved Suction Device for Draining Wounds, Arch. Surg., May 1972, 104, p. 707. |
| Linden, Willem van der, et al, “Randomized Trial of Drainage After Cholecystectomy: Suction Versus Static Drainage Through a Main Wound Versus a Stab Incision”, American Journal of Surgery, Feb. 1981, vol. 141, pp. 289-294. |
| Mcfarlane, R.M., The Use of Continuous Suction under Skin Flaps, Br. Journ. Plast. Surg., pp. 77-86. |
| Mclaughlan, J, et al, “Sterile Microenvironment for Postoperative Wound Care”, The Lancet, Sep. 2, 1978, pp. 503-504. |
| Meyer, W. and V. Schmeiden, Bier's Hyperemic Treatment, Published 1908 W. B. Saunders Company, pp. 44-65. |
| Morykwas, Michael J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation”, Ann Plast Surg 1997;38:553-562 (Dec. 10, 1996). |
| Nakayama, Y, et al, “A New Method for the Dressing of Free Skin Grafts”, Plastic and Reconstructive Surgery, Dec. 1990 pp. 1216-1219, UK. |
| NURSING75, Wound Suction: Better Drainage with Fewer Problems, Nursing, vol. 5, No. 10, Oct. 1975, pp. 52-55. |
| Office Action (Final) for U.S. Appl. No. 10/575,875, published as 2007/129,707, dated Jun. 17, 2009 in 19 pages. |
| Ramirez, O.M., et al., Optimal Wound Healing under Op-Site Dressing, Ideas and Innovations, 73(3), pp. 474-475. |
| Ranson, J. H. C., et al, “Safer Intraperitoneal Sump Drainage”, Surgery, Gynecology & Obstetrics, Nov. 1973, vol. 137, pp. 841-842. |
| Sames, C.P., Sealing of Wounds with Vacuum Drainage, Br. Med. Journ., Nov. 5, 1977, p. 1223, Correspondence. |
| Solovev, V. A., et al., “The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract—Guidelines” USSR Ministry of Health, S. M. Kirov Gorky State Medical Institute, 1987 (with English translation). |
| Solovev, V.A. “Treatment and Prevention of Suture Failures after Gastric Resection” (Dissertation Abstract) (S.M. Kirov Gorky State Medical Institute, Gorky USSR 1988). |
| Stewart, Joanne, Ph.D., World Wide Wounds—Next generation of products for wound management—2002 (13 pages). |
| Svedman, P., “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers,” Scand J. Plast. Reconst. Surg., 19:211-213, 1985. |
| Svedman, P., “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 1983, 532-34. |
| Svedman, P., A Dressing Allowing Continuous Treatment of a Biosurface, IRCS Med. Science: Biomed. Tech.; Clinic. Med.; Surg. and Transplantation, 1979, 7, p. 221. |
| Svedman, P., et al., “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent irrigation,” Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
| Swift, et al, “Quorum Sensing in Aeromonas hydrophila and Aeromonas salmoncida: Identification of LuxRI Homologs AhyRI and AsaRI and Their Cognate N-Acylhomoserine Lactone Signal Molecules,” J. Bacteriol., 179(17):5271-5281 (1997). |
| Teder and Svedman et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, 1990, vol. 3, pp. 399-407. |
| Tribble, David E. M.D., An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery New York, pp. 511-513, 1972 vol. 105. |
| Usupov, Y. N., et al., “Active Wound Drainage”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 8-10. |
| Venturi, Mark L., “Mechanisms and Clinical Applications of the Vacuum-Assisted Closure (VAC) Device”, Am J Clin Dermatol (2005) 693, 185-194; Review Article (2005),185-194. |
| Vijanto, J. and J. Raekallio, Local Hyperalimentation of Open Wounds, Br. J. surg., 1976, 63, 427-430. |
| Wackenfors, A., et al., Effects of Vacuum-Assisted Closure Therapy on Inguinal Wound Edge Microvascular Blood Flow, Wound Rep. Reg, 2004, 12, 600-606. |
| Webb, New Techniques in Wound Management: Vacuum-Assisted Wound Closure, Journal of the American Academy of Orthopaedic Surgeons, v. 10, No. 5, pp. 303-311, Sep. 2002. |
| Webster's Revised Unabridged Dictionary, published 1913 by C. & G. Merriam Co., definition of Flapper Valve, downloaded from Free Online Dictionary. |
| Westaby, S., et al., “A Wound Irrigation Device”, The Lancet, Sep. 2, 1978, pp. 503-504. |
| Wooding-Scott, Margaret, et al., “No Wound is Too Big for Resourceful Nurses,” RN Dec. 1988, pp. 22-25 USA. |
| Wound Suction, Nursing, Oct. 1975, USA pp. 52-53. |
| Wu, W.S., et al. Vacuum therapy as an intermediate phase in would closure: a clinical experience, Eur J Plast Surg (2000) 23: pp. 174-177. |
| Number | Date | Country | |
|---|---|---|---|
| 20100100063 A1 | Apr 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11610458 | Dec 2006 | US |
| Child | 12592049 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11432855 | May 2006 | US |
| Child | 11610458 | US |
